Stock Screener App

Gratuito -

Installare

0.9352

1.50% -0.0142

Cognition Therapeutics Inc (CGTX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie

Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey

Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

CGTX|Cognition Therapeutics Inc|Price:0.941|Chg%:+0.021 - TradingKey

Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey

Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey

Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey

Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView

Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

CGTX|Cognition Therapeutics Inc|Price:0.929|Chg%:+0.010 - TradingKey

Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr

Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm

Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et

RANI Stock Price and Chart — NASDAQ:RANI - TradingView

Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative

Alzheimer’s drug developer to outline Lewy body dementia Phase 3 plan - Stock Titan

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit - GlobeNewswire

Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Number of shareholders of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa

Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo

Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Growth Benchmark - marketscreener.com

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index - marketscreener.com

Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33% - MSN

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index - marketscreener.com

Cognition, FDA agree on late-stage trial for dementia therapy - MSN

symbol__ Stock Quote Price and Forecast - CNN

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha

H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail

Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView

H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo

CGTX Forecast — Price Target — Prediction for 2027 - TradingView

CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Share RallyHealthcare Earnings Report - dars.gov.et

Cognition Therapeutics | 10-K: FY2025 Annual Report - Moomoo

FDA says DLB psychosis could be approvable in Cognition trial plan - Stock Titan

Cognition Therapeutics receives FDA alignment on Phase 3 trial of zervimesine for DLB psychosis - grafa.com

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% - TradingView

Cognition Therapeutics Secures FDA Alignment for Pivotal Phase 3 Trial of Zervimesine in DLB Psychosis, Targeting First Durable Treatment Option 1 – Minichart - Minichart

Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) - Yahoo Finance

Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment - marketscreener.com

Cognition Therapeutics stock rises on FDA trial alignment By Investing.com - Investing.com Canada

Cognition Therapeutics aligned with FDA on pivotal Phase 3 design for zervimesine in DLB psychosis - TradingView

Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis - Quiver Quantitative

Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine - Stock Titan

Cognition Therapeutics Aligns on Key Aspects of Pivotal - GlobeNewswire

Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria

Form 4 Cognition Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Cognition Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Khattar Jack A. - Moomoo

Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs - Stock Titan

BNTX

$92.38

0.96%

INCY

$122.50

2.78%

ROIV

$34.30

0.92%

RPRX

$59.01

0.63%

ONC

$328.38

1.12%

ALNY

$284.60

4.16%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters